Biolife Solutions (NASDAQ:BLFS) Director Thomas Girschweiler sold 1,025,000 shares of the business’s stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $5.26, for a total transaction of $5,391,500.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Biolife Solutions stock opened at $7.02 on Thursday. Biolife Solutions has a fifty-two week low of $2.01 and a fifty-two week high of $7.83. The stock has a market cap of $105.24, a P/E ratio of -33.43 and a beta of 0.37.
Biolife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, March 8th. The medical equipment provider reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Biolife Solutions had a negative return on equity of 37.37% and a negative net margin of 22.82%. The firm had revenue of $3.13 million for the quarter, compared to analysts’ expectations of $3.10 million. analysts predict that Biolife Solutions will post -0.09 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN purchased a new position in Biolife Solutions during the fourth quarter worth about $111,000. Millennium Management LLC boosted its holdings in Biolife Solutions by 901.6% during the fourth quarter. Millennium Management LLC now owns 182,550 shares of the medical equipment provider’s stock worth $1,095,000 after purchasing an additional 164,324 shares during the last quarter. Finally, Essex Investment Management Co. LLC boosted its holdings in Biolife Solutions by 199.8% during the fourth quarter. Essex Investment Management Co. LLC now owns 254,096 shares of the medical equipment provider’s stock worth $1,525,000 after purchasing an additional 169,341 shares during the last quarter. Institutional investors and hedge funds own 12.09% of the company’s stock.
Several equities research analysts have recently commented on BLFS shares. Maxim Group set a $8.00 target price on shares of Biolife Solutions and gave the stock a “buy” rating in a research report on Thursday, January 4th. Northland Securities started coverage on shares of Biolife Solutions in a research report on Monday, March 12th. They set an “outperform” rating for the company. Finally, ValuEngine raised shares of Biolife Solutions from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd.
WARNING: “Thomas Girschweiler Sells 1,025,000 Shares of Biolife Solutions (BLFS) Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/12/thomas-girschweiler-sells-1025000-shares-of-biolife-solutions-blfs-stock.html.
About Biolife Solutions
BioLife Solutions, Inc develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death.
Receive News & Ratings for Biolife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.